Acetyl L-Carnitine aids diabetic neuropathyEfficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy.
We investigated the effects of a combination treatment that includes Acetyl L-Carnitine on diabetic neuropathy in patients with Type 2 diabetes. In a 12-month, double-blind, placebo-controlled study involving 85 participants, we observed that those receiving the combination treatment showed significant improvements in several measures of nerve function, pain, and quality of life. However, results for cardiovascular reflex tests and certain screening instruments did not show significant benefits. Overall, the combination appears promising for managing diabetic neuropathy.
Read More
Acetyl-l-carnitine benefits heart functionAcetyl-l-carnitine and oxfenicine on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar rats.
This study examined how acetyl-l-carnitine affects heart function in diabetic male Wistar rats. We induced diabetes and treated the rats with acetyl-l-carnitine or oxfenicine for eight weeks.
Our findings highlighted that acetyl-l-carnitine helped to maintain heart mechanics by preventing deterioration in cardiac contractility, unlike oxfenicine. This suggests that acetyl-l-carnitine could support heart health in diabetes, offering insights for future treatments.
Read More
Carnitine supplementation shows promiseCarnitine supplementation improves insulin sensitivity and skeletal muscle acetylcarnitine formation in patients with type 2 diabetes.
We explored the potential benefits of carnitine supplementation in individuals with type 2 diabetes over a 12-week period. Our study involved 32 participants taking 2970 mg of L-carnitine daily, while we measured insulin sensitivity and acetylcarnitine levels in their muscles.
The results showed that carnitine treatment improved insulin sensitivity and increased acetylcarnitine concentrations in muscle. Additionally, there were hints of lower fasting plasma glucose levels and reduced liver fat content.
Although the benefits are promising, further research is essential to solidify these findings.
Read More
ALC matches MC efficacy in neuropathyEffects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial.
We investigated how acetyl-L-carnitine (ALC) compares to methylcobalamin (MC) in treating diabetic peripheral neuropathy. In this rigorous clinical trial involving 232 patients, we found that both ALC and MC led to noticeable improvements in nerve function and symptoms over 24 weeks.
Importantly, there was no significant difference in the effectiveness between the two treatments. This suggests that ALC is just as good as MC for managing this condition, with both options being well-tolerated by patients.
Read More
Acetyl-L-carnitine ineffective for nerve healthIdentification of factors associated with sural nerve regeneration and degeneration in diabetic neuropathy.
We explored how acetyl-L-carnitine affects nerve regeneration in patients with diabetic neuropathy (DN). In a year-long study, we reviewed various data from nearly 500 DN patients to identify factors influencing nerve health. We discovered that higher levels of HbA1c, a marker of blood glucose control, were linked to poorer nerve fiber performance.
Unfortunately, the data did not indicate significant benefits from acetyl-L-carnitine in nerve regeneration compared to blood sugar management. This highlights the importance of keeping blood sugar levels stable to protect nerve function.
Read More